BioSpace News Archive

Drug Development

Eyenovia Publication of EYE 102 Phase II Results Demonstrates Strong Pharmacodynamic Effect, Tolerability and Reduced Systemic Exposure of High-Precision Micro-dosing compared to Conventional Eyedroppers

Eyenovia’s micro-dose delivery of topical phenylephrine achieves comparable dilation results with a dose one-quarter the volume of a conventional pipette eye dropper.

October 30, 2017

·

4 min read

Business

Arena to Release Third Quarter 2017 Financial Results and Provide Corporate Update on Tuesday, November 7

Arena, today announced that the Company will release its third quarter 2017 financial results and provide a corporate update on Tuesday, November 7, 2017, after the close of the U.S. financial markets.

October 30, 2017

·

2 min read

Business

Infinity Announces the Date of its Third Quarter 2017 Financial Results Conference Call and Webcast

Infinity Pharma will host a conference call on Tuesday, November 7, 2017, at 4:30 p.m. ET to review its third quarter 2017 financial results and provide an update on the company.

October 30, 2017

·

1 min read

Business

Michael J. Fox Foundation and 23andMe Announce Collaboration to Capture Parkinson’s Experience at Scale and Amplify Patient Voice in Research and Care

The Michael J. Fox Foundation for Parkinson’s Research and 23andMe announced a collaboration to build a large, diverse cohort of both patients and control volunteers who have consented to participate in research.

October 30, 2017

·

6 min read

Drug Development

HedgePath Pharma Completes Enrollment for its Phase 2(b) Trial in BCCNS and Provides Trial Update

HedgePath Pharma announced today that it has completed enrollment in its previously announced open label, Phase 2b SCORING clinical trial, testing SUBA-Itraconazole in patients with BCCNS.

October 30, 2017

·

9 min read

Deals

BERG Enters Into an Agreement With Sanofi Pasteur to Identify Biomarkers of Flu Vaccine Performance

BERG today announced a new research effort with Sanofi Pasteur, the influenza vaccine global leader.

October 30, 2017

·

3 min read

Policy

Bayer Announces BAY94-9027 BLA Accepted by FDA

The FDA has accepted Bayer’s BLA filing for BAY94-902 for the treatment of hemophilia A in adults and adolescents 12 years of age and over.

October 30, 2017

·

4 min read

Drug Development

Can-Fite Announces Enrollment of First Patient in Its ACRobat Phase III Trial of Piclidenoson in Rheumatoid Arthritis

This randomized, double-blind, active and placebo-controlled study will enroll approximately 500 patients through clinical sites in Europe, Israel and Canada.

October 30, 2017

·

6 min read

Policy

NewLink Genetics Announces FDA Orphan-Drug Designation for Indoximod

Indoximod is aimed at treating patients with Stage IIb-IV melanoma.

October 30, 2017

·

3 min read

Business

Marrone Bio Innovations to Report Third Quarter 2017 Financial Results and Host a Conference Call on Monday, November 13th at 1:30 p.m. Pacific Time

Management will host an investor conference call the same day to discuss the results, provide a corporate update, and conclude with a Q&A from participants.

October 30, 2017

·

3 min read